Brief: Nanobiotix FY Net Loss Widens To EUR 47 Mln

Nanobiotix SA

31/03/2022 10:11

March 31 (Reuters) - NANOBIOTIX SA  NANOB.PA :
    * ON WEDNESDAY, NANOBIOTIX PROVIDED BUSINESS UPDATE AND
REPORTED
FULL YEAR 2021 FINANCIAL RESULTS
    * EXPECT TO PROVIDE UPDATED STUDY 1100 DATA AT A MEDICAL
CONFERENCE DURING Q4 OF 2022
    * DETERMINATION OF RECOMMENDED PHASE II DOSE FOR NBTXR3 IN
PANCREATIC CANCER EXPECTED IN 2022
    * ANTICIPATES THAT CASH AND CASH EQUIVALENTS OF EUR 83.9
MILLION
AS OF DECEMBER 31, 2021, WILL FUND ITS OPERATIONS INTO Q2 OF
2023
    * NEW DATA FROM EXPANSION STUDY 102 IN HIGH-RISK, LA-HNSCC
PATIENTS HIGHLIGHTS POTENTIAL CLINICAL BENEFIT OF NBTXR3 SHOWING
A MEDIAN OVERALL SURVIVAL REACHING 23 MONTHS IN EVALUABLE
PATIENTS
    * DATA WITH MINIMUM FOLLOW-UP OF ONE YEAR FOR FULL STUDY
POPULATION ANTICIPATED IN MID-2023
    * PIVOTAL PHASE III STUDY, NANORAY-312, NOW ACTIVELY
ENROLLING
ELDERLY, LA-HNSCC PATIENTS INELIGIBLE FOR CISPLATIN ACROSS
MULTIPLE EUROPEAN SITES WITH US SITE ACTIVATION ANTICIPATED IN
MID-2022
    * FY REVENUE EUR 10,000 VS EUR 50,000 YR AGO
    * FY OPERATING LOSS EUR 52.6 MLN VS LOSS EUR 36.4 MLN YR AGO
    * FY NET LOSS EUR 47.0 MLN VS LOSS EUR 33.6 MILLION

Source text for Eikon:  ID:nBw7V8MYla 
Further company coverage:  NANOB.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))